UA118239C2 - Сполука-коагоніст gip і glp-1 - Google Patents

Сполука-коагоніст gip і glp-1

Info

Publication number
UA118239C2
UA118239C2 UAA201707109A UAA201707109A UA118239C2 UA 118239 C2 UA118239 C2 UA 118239C2 UA A201707109 A UAA201707109 A UA A201707109A UA A201707109 A UAA201707109 A UA A201707109A UA 118239 C2 UA118239 C2 UA 118239C2
Authority
UA
Ukraine
Prior art keywords
gip
glp
agonist compounds
incretinomimetic
glucagon
Prior art date
Application number
UAA201707109A
Other languages
English (en)
Inventor
Хорхе Алсіна-Фернандес
Бенгт Крістер Буквист
Тамер Коскан
Роберт Чадуік Каммінз
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA118239(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA118239C2 publication Critical patent/UA118239C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Винахід стосується сполуки, яка являє собою інкретиноміметик подвійної дії, який є агоністом рецепторів як людського глюкозозалежного інсулінотропного поліпептиду (GIP), так і глюкагоноподібного пептиду-1 (GLP-1), і може бути корисною для лікування цукрового діабету другого типу (T2D).
UAA201707109A 2015-01-09 2016-05-01 Сполука-коагоніст gip і glp-1 UA118239C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09
PCT/US2016/012124 WO2016111971A1 (en) 2015-01-09 2016-01-05 Gip and glp-1 co-agonist compounds

Publications (1)

Publication Number Publication Date
UA118239C2 true UA118239C2 (uk) 2018-12-10

Family

ID=55315708

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201707109A UA118239C2 (uk) 2015-01-09 2016-05-01 Сполука-коагоніст gip і glp-1

Country Status (45)

Country Link
US (1) US9474780B2 (uk)
EP (2) EP3597662A1 (uk)
JP (3) JP6219534B2 (uk)
KR (4) KR102330764B1 (uk)
CN (2) CN107207576B (uk)
AR (1) AR103242A1 (uk)
AU (1) AU2016205435B2 (uk)
CA (1) CA2973352C (uk)
CL (1) CL2017001760A1 (uk)
CO (1) CO2017006737A2 (uk)
CR (1) CR20170310A (uk)
CY (2) CY1122028T1 (uk)
DK (1) DK3242887T3 (uk)
DO (1) DOP2017000153A (uk)
EA (3) EA202090392A3 (uk)
EC (1) ECSP17043648A (uk)
ES (1) ES2747928T3 (uk)
FI (1) FIC20230005I1 (uk)
FR (1) FR23C1006I2 (uk)
HR (1) HRP20191614T1 (uk)
HU (2) HUE045860T2 (uk)
IL (3) IL252499B (uk)
JO (2) JOP20200119A1 (uk)
LT (2) LT3242887T (uk)
MA (2) MA50422A (uk)
MD (1) MD3242887T2 (uk)
ME (1) ME03494B (uk)
MX (2) MX2017008927A (uk)
MY (1) MY193616A (uk)
NL (1) NL301217I2 (uk)
NO (1) NO2023005I1 (uk)
NZ (1) NZ732000A (uk)
PE (1) PE20170954A1 (uk)
PH (1) PH12017501252A1 (uk)
PL (1) PL3242887T3 (uk)
PT (1) PT3242887T (uk)
RS (1) RS59146B1 (uk)
SG (1) SG11201705603YA (uk)
SI (1) SI3242887T1 (uk)
SV (1) SV2017005453A (uk)
TN (1) TN2017000198A1 (uk)
TW (1) TWI582109B (uk)
UA (1) UA118239C2 (uk)
WO (1) WO2016111971A1 (uk)
ZA (1) ZA201703930B (uk)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3624828B1 (en) 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Pharmaceutical formulation comprising incretin-insulin conjugates
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
KR102379958B1 (ko) * 2018-05-04 2022-04-01 노보 노르디스크 에이/에스 Gip 유도체 및 이의 용도
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020023382A1 (en) * 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
US20230293638A1 (en) * 2018-07-23 2023-09-21 Eli Lilly And Company Method of using a gip/glp1 co-agonist for diabetes
CA3107345A1 (en) * 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
JP7511548B2 (ja) 2018-09-24 2024-07-05 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
TWI799680B (zh) 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
AR119471A1 (es) 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
PE20221049A1 (es) 2019-08-19 2022-06-30 Lilly Co Eli Metodos para preparar analogos de incretina
JP2022551282A (ja) 2019-10-04 2022-12-08 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
BR112022014397A2 (pt) 2020-01-23 2022-10-11 Lilly Co Eli Compostos co-agonistas de gip/glp1
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
KR20220145888A (ko) 2020-03-06 2022-10-31 사노피 선택적 gip 수용체 작용제로서의 펩티드
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023000229A2 (pt) 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
CA3184717A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonists at glp-1 and gip receptors suitable for oral delivery
CN114729060B (zh) * 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
CA3195155A1 (en) 2020-10-17 2022-04-21 Rajamannar Thennati Glp-1/gip dual agonists
AU2021391241B2 (en) * 2020-12-02 2024-05-09 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Lactam-modified polypeptide compounds
AU2022210988B9 (en) * 2021-01-20 2023-12-14 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CA3208208A1 (en) 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Tirzepatide therapeutic methods
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
US20240150425A1 (en) * 2021-03-25 2024-05-09 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
EP4317179A1 (en) * 2021-03-25 2024-02-07 BrightGene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
US20240226017A1 (en) 2021-05-07 2024-07-11 Eli Lilly And Company Erodible tablet
CN117866050A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
EP4345105A1 (en) * 2021-06-01 2024-04-03 Nanjing Zhine Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202302624A (zh) * 2021-06-18 2023-01-16 大陸商廣東眾生睿創生物科技有限公司 含內醯胺橋的多肽化合物
CN118159552A (zh) 2021-09-06 2024-06-07 赛诺菲 作为强效的且选择性的gip受体激动剂的新肽
MX2024003236A (es) * 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023089594A1 (en) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (zh) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
WO2024006662A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024012472A1 (zh) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN117756913A (zh) * 2022-11-07 2024-03-26 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
WO2024112617A2 (en) 2022-11-21 2024-05-30 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
WO2024145638A2 (en) 2022-12-29 2024-07-04 Eli Lilly And Company Processes and intermediates for preparing tirzepatide
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP5410020B2 (ja) * 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US9072703B2 (en) * 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
NZ611878A (en) * 2010-12-22 2015-02-27 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
BR112014006684A2 (pt) * 2011-09-23 2017-03-28 Novo Nordisk As análogos de glucagon
AP2014007797A0 (en) * 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
TWI689515B (zh) * 2012-05-03 2020-04-01 丹麥商西蘭製藥公司 Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法
CA2877358A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2014060512A1 (en) 2012-10-17 2014-04-24 Novo Nordisk Health Care Ag Fatty acid acylated amino acids for growth hormone delivery
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina

Also Published As

Publication number Publication date
CN107207576B (zh) 2020-11-24
EA031591B1 (ru) 2019-01-31
JOP20200119A1 (ar) 2017-06-16
ECSP17043648A (es) 2017-11-30
PT3242887T (pt) 2019-10-29
WO2016111971A1 (en) 2016-07-14
PE20170954A1 (es) 2017-07-13
LTPA2023504I1 (uk) 2023-02-27
RS59146B1 (sr) 2019-09-30
MA41315B1 (fr) 2019-11-29
EP3597662A1 (en) 2020-01-22
IL252499B (en) 2020-08-31
CY2023003I2 (el) 2023-06-09
JO3575B1 (ar) 2020-07-05
DOP2017000153A (es) 2017-07-15
IL252499A0 (en) 2017-07-31
HRP20191614T1 (hr) 2019-12-13
MX2021005835A (es) 2021-07-15
HUE045860T2 (hu) 2020-01-28
AR103242A1 (es) 2017-04-26
EA202090392A3 (ru) 2020-08-31
TN2017000198A1 (en) 2018-10-19
NZ748274A (en) 2022-03-25
NZ732000A (en) 2018-11-30
CA2973352C (en) 2019-03-26
EP3242887B1 (en) 2019-08-14
CL2017001760A1 (es) 2018-03-16
SG11201705603YA (en) 2017-08-30
CR20170310A (es) 2017-08-17
JP6545766B2 (ja) 2019-07-17
JP2018052933A (ja) 2018-04-05
NL301217I2 (nl) 2023-04-04
MY193616A (en) 2022-10-20
JP2017507124A (ja) 2017-03-16
NO2023005I1 (no) 2023-02-02
CY1122028T1 (el) 2020-10-14
MA50422A (fr) 2020-08-26
AU2016205435B2 (en) 2018-03-29
ES2747928T3 (es) 2020-03-12
CO2017006737A2 (es) 2017-09-29
EA201892057A1 (ru) 2019-02-28
CY2023003I1 (el) 2023-03-24
IL276492B (en) 2021-04-29
MD3242887T2 (ro) 2019-11-30
MA41315A (fr) 2017-11-15
MX2017008927A (es) 2017-10-11
EA035055B1 (ru) 2020-04-22
SV2017005453A (es) 2018-08-27
IL276492A (en) 2020-09-30
KR20230023822A (ko) 2023-02-17
HUS2300006I1 (hu) 2023-02-28
ZA201703930B (en) 2019-06-26
CA2973352A1 (en) 2016-07-14
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
IL281545A (en) 2021-05-31
FIC20230005I1 (fi) 2023-02-02
LT3242887T (lt) 2019-11-11
SI3242887T1 (sl) 2019-10-30
KR20170092661A (ko) 2017-08-11
ME03494B (me) 2020-01-20
TWI582109B (zh) 2017-05-11
DK3242887T3 (da) 2019-09-02
FR23C1006I1 (fr) 2023-03-24
EA202090392A2 (ru) 2020-05-31
EA201791281A1 (ru) 2017-11-30
BR112017010596A2 (pt) 2018-03-06
KR20210145311A (ko) 2021-12-01
KR20190026967A (ko) 2019-03-13
PL3242887T3 (pl) 2020-02-28
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30
CN112608377B (zh) 2024-02-13
JP6219534B2 (ja) 2017-10-25
US20160199438A1 (en) 2016-07-14
AU2016205435A1 (en) 2017-06-08
JP2019203000A (ja) 2019-11-28
NL301217I1 (uk) 2023-02-15
TW201636362A (zh) 2016-10-16
FR23C1006I2 (fr) 2024-01-05
CN112608377A (zh) 2021-04-06
CN107207576A (zh) 2017-09-26
JP6754867B2 (ja) 2020-09-16
EP3242887A1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
MY197569A (en) Gip/glp1 co-agonist compounds
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
EA035466B9 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
DK3806855T3 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
MX2019006429A (es) Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip.
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
PT4097099T (pt) Agonistas heterocíclicos de glp-1
UA118558C2 (uk) Пептидна сполука
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
EA202191379A1 (ru) Комбинированное лечение nafld и nash
PH12017501205A1 (en) Glucagon derivatives
EP3305316A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SARCOPENIA COMPRISING A PEPTIDE-1 RECEPTOR AGONIST SIMILAR TO GLUCAGON
EP3438091A4 (en) CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
DK3406264T3 (da) Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)